Antibody Drug Conjugates:
Targeted Cancer Therapies at the Intersection of Chemistry, Biology, and Engineering
Friday, June 27, 2025
The 23rd Annual Koch Institute Symposium on Antibody Drug Conjugates: Targeted Cancer Therapies at the Intersection of Chemistry, Biology, and Engineering will take place on Friday, June 27, 2025. We cordially invite scientists, oncologists, and any other member of the biomedical community to join us in a day of engaging talks, stimulating conversations with colleagues, and of course camaraderie in our collective fight against cancer.
Agenda
9:00 a.m. - 9:10 a.m. Opening remarks
Matthew Vander Heiden
Director, MIT Koch Institute
9:10 a.m. – 10:00 a.m. Keynote
Introduction: Jessica Stark, MIT Koch Institute
Carolyn Bertozzi
Stanford University
Topic: Antibody drug conjugate biological chemistry
10:00 a.m. – 12:00 pmSession One
Peter Senter
Pfizer
Topic: Antibody drug conjugate history
Gerold Meinhardt
Daiichi Sankyo
Topic: Enhertu
Alison Betts
Takeda Pharmaceuticals
Topic: Antibody drug conjugate quantitative systems pharmacology
Tim Lowinger
Mersana Therapeutics
Topic: Immunostimulatory antibody drug conjugates
12:00 p.m. – 1:30 p.m.Lunch Break
1:30 p.m. – 2:30 p.m.Session Two: Short Presentations
Laurie Boyer
MIT Koch Institute
Topic: Lysosome morphology as predictor of drug efficacy
Dane Wittrup
MIT Koch Institute
Topic: Noncovalent capture antibody drug conjugates
Jeremiah Johnson
MIT Koch Institute
Topic: Antibody-polymer conjugates
Dasa Lipovsek
Aktis Oncology
Topic: Radioligand therapy
2:30 p.m. – 4:30 p.m.Session Three
Greg Thurber
University of Michigan
Topic: Strategies for uniform antibody drug conjugate penetration
Puja Sapra
AstraZeneca
Topic: Antibody drug conjugate payloads and linker chemistry